A breakdown of the challenges and solutions within in vitro toxicology assay development

When you need an ophthalmology specialist with a proven track record in ocular pharmacology, DMPK and safety studies - look no further. We offer diverse experience in ophthalmology across multiple indications, in both anterior and posterior segments, as well as in rare ocular diseases, cell and gene therapies and ophthalmic devices.

Antibody-drug conjugates (ADCs) continue to be a widely used and key modality of interest for the pharmaceutical industry due to their ability to deliver targeted cytotoxic payloads to solid tumors and blood-based malignancies that induce cell apoptosis for oncology patients.

CYTO 2024 -- Chimeric antigen receptors (CARs) are engineered proteins expressed on the surface of modified T cells in order to direct the binding of resulting CAR T cells to targets expressed on malignant cells.

CYTO 2024 -- Basophils are circulating white blood cells that express CD63 marker upon activation of Fc?RI? receptor. Basophil activation/degranulation measurement via CD63 expression, can be used as a pharmacodynamic (PD) biomarker to assess target engagement, inform on drug dose selections and drug efficacy in clinical trials.

CYTO 2024 -- Chronic lymphocytic leukemia (CLL) is the one of the most frequent types of leukemia in western countries and mainly occurs in elderly patients. This type of cancer has an overall survival of 5 years that ranges from 20% among very high-risk patients to more than 90% in those with less-aggressive genetic risk features.

CYTO 2024 -- Adoptive cell therapies (ACT) have emerged as a promising frontier in cancer and autoimmune disorders, harnessing the power of the immune system to combat diseases. However, the full potential of ACT remains elusive, often hindered by challenges such as variable patient responses and limited persistence of infused cells.

WRIB 2024 -- Here we discuss a high-performance liquid chromatography tandem mass spectrometry (LC-MS/MS) method to simultaneously quantify 15 human bile acids (BAs) in patient plasma and the specific validation tests performed to provide analytical data support for clinical studies.

SETAC Europe 2024 -- In the course of conducting OECD 307 and OECD 308 studies, the amount of test substance and its metabolites extracted from the soil or sediment can decline over time, leading to an increase in the amount of residues remaining unextracted. This can only be quantified where radiolabeled test item has been applied.

SETAC Europe 2024 -- Imagine one individual in a crowd of 100,000 people - they would be difficult to locate. But give this individual a large flag to wave and there they are - easy to see. In addition, as they move through the crowd, you can track and follow where they go and the path they have taken.